691 Followers on Owler

Exelixis

, developing small molecule therapies for the treatment of cancer... Read more
OverviewCompetitorsFundingInvestmentsNews & Insights

Exelixis

, developing small molecule therapies for the treatment of cancer... Read more
Exelixis President & CEO: Michael M. Morrissey

President & CEO

Michael M. Morrissey

CEO Approval Rating

51/100

1994

PublicNASDAQEXEL

Pharmaceuticals & Biotechnology
Biotechnology
28342836 NAICS listing

Annual Revenue
$2.4B
Employees
1,220
Funding
$432.3M
Investments
1

News

Conference Presentation
Sep 01, 2026
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Partnership
May 20, 2026
Zacks
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

Exelixis Competitors

1Agios
2Allergan
3TESARO
4Nektar Therapeutics
5Diffusion Pharmaceuticals
6Monopar Therapeutics
7Advanced Chemotherapy Technologies
8ArriVent
9Allorion
10Biogen
Unlock 16 + competitors

Trending Companies